ArticleJournal of clinical microbiology2025
Evaluation of MicroScan and VITEK 2 systems for susceptibility testing of Enterobacterales with updated breakpoints.
Article in Journal of clinical microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Comparative analysis of disk diffusion and microscan versus broth microdilution methods for determining antimicrobial susceptibility of cefepime and piperacillin-tazobactam inAntimicrobial agents and chemotherapy · 2026Article
- Cefepime susceptibility testing in AmpC-hyperproducing Enterobacter cloacae complex: limitations of routine methods and a pragmatic diagnostic approach.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Reply to McArdle and Austin, "Further detail required to assess additional evidence on agreement between VITEK 2 and broth microdilution piperacillin/tazobactam testing in cephalosporin resistant Enterobacterales".Journal of clinical microbiology · 2026Article
- Further detail required to assess additional evidence on agreement between VITEK 2 and broth microdilution piperacillin/tazobactam testing in cephalosporin resistant Enterobacterales.Journal of clinical microbiology · 2026Article
- Evolving Approaches to Bacterial Identification: A Review of Classical and Modern Techniques.International journal of molecular sciences · 2026Review
- Clinical, Pathological, and Antimicrobial Characteristics ofVeterinary sciences · 2026Article
- Deep Learning-Based Rapid Identification ofRisk management and healthcare policy · 2026Article
- False equivalence: differences in theJAC-antimicrobial resistance · 2025Article
- Evaluation of a Novel Rapid Phenotypic Antimicrobial Susceptibility Testing System.Antibiotics (Basel, Switzerland) · 2025Article
- Article
- Comparative study on the time trends of antimicrobial resistance at animal and human hospitals in a shared community.One health (Amsterdam, Netherlands) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We compared the performance of two commercial antimicrobial susceptibility testing (AST) systems for contemporary Enterobacterales strains using broth microdilution (BMD) as the reference standard with 2022 Clinical and Laboratory Standards Institute or current FDA breakpoints applied. Enterobacterales clinical isolates with BMD results were tested in parallel using VITEK 2 AST test cards (N802, XN15, bioMérieux, Hazelwood, MO, USA) and MicroScan NM56 AST panels (Beckman Coulter, Sacramento, CA, USA). The 200 isolates (57
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.